Plain-English translation of NCT07599670 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called designed to treat Alzheimer's disease by targeting a protein buildup in the brain. The study will check whether the medication is safe, how well it works, and how your body processes it. You'll receive either the medication or a placebo injection once a month for six months, then be followed for an additional three months.
Alzheimer's disease causes progressive memory loss and cognitive decline with no cure. This medication targets amyloid, a protein that accumulates in the brains of people with Alzheimer's, and researchers hope it may slow the disease's progression.
You likely qualify if…
You likely don't qualify if…
You will visit a study clinic or hospital regularly over 36 weeks total: six months of receiving injections once every four weeks, followed by three months of follow-up visits. At each visit, you'll have physical exams, blood tests, and questionnaires to assess your safety and how you're doing. There's also an optional extension phase where you can continue the treatment (blinded) for up to 12 months based on your brain scan results.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States